EGFR and breast carcinoma: In breast cancer, EGFR is overexpressed [10, 11] and can retro-translocate to the nucleus [12–17], potentially contributing to the underwhelming success of conventional EGFR tyrosine kinase inhibitor (TKI) and antibody-based therapies [18–22] in breast cancer.